XML 29 R19.htm IDEA: XBRL DOCUMENT

Subsequent Event	9 Months Ended
Subsequent Event	Sep. 30, 2016
Subsequent Event
Subsequent Event	13.Subsequent Event In October 2016 the Company announced that the first patient had been dosed in its Phase 2 study of MGL-3196 for the treatment of non-alcoholic steatohepatitis (NASH), which triggered a milestone payment under the Research, Development and Commercialization Agreement with Roche (see Note 12).